Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin. It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).
Bacterial inhibitor Related Products:
Pretomanid; Pyrazinamide; Sulfanilamide; Walrycin B; Daptomycin; Tigecycline; Rifabutin; Biapenem; Teicoplanin; Cefditoren Pivoxil; Cefdinir; Azithromycin; Trimethoprim; Vancomycin HCl; Amoxicillin; Cefoxitin acid; Ceftibuten dihydrate; Besifloxacin; Solithromycin; Cefditoren; Dalbavancin HCl; Cefoxitin Sodium; Besifloxacin Hydrochloride; Pleuromutilin